Last reviewed · How we verify
Katadolon (FLUPIRTINE)
At a glance
| Generic name | FLUPIRTINE |
|---|---|
| Drug class | flupirtine |
| Target | Serine hydroxymethyltransferase, mitochondrial, Potassium voltage-gated channel subfamily KQT member 2, Potassium voltage-gated channel subfamily KQT member 3 |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Peripheral KV7 Activation for Pain Relief (EARLY_PHASE1)
- Flupirtine as Oral Treatment in Multiple Sclerosis (PHASE2)
- Effect of the Kv7-channel Opener Flupirtine on the Excitability of Human Peripheral Myelinated Axons in Vivo (PHASE1)
- Pharmacokinetics, Metabolism and Analgesic Effects of Flupirtine (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Katadolon CI brief — competitive landscape report
- Katadolon updates RSS · CI watch RSS